Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Durvalumab Plus Chemoradiotherapy vs Chemoradiotherapy Alone in Locally Advanced Cervical Cancer
jRCT2080224829Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Cervical Cancer (CC) comparing Durvalumab + Standard-of-care CCRT with Placebo + Standard-of-care CCRT (2 arms). Primary endpoint: Progression-free survival. Started Aug 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on jRCT2080224829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224829.